An observational study in Atrial Fibrillation, sponsored by Bayer. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by Bayer · Observational
Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's enrollment of 2,251 is above the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Bayer is the lead sponsor of 1,643 studies on the registry; 56 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 130 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients taking rivaroxaban for stroke prevention in atrial fibrillation attending consults of hematology, cardiology and internal medicine
Exclusion Criteria:
Patients with Atrial fibrillation treated with Rivaroxaban
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Patients treated by Physicians under approved local prescriptions
Demographic Data
Time frame: At recruitment visit
Medical History
Time frame: At recruitment visit
Assess regional differences among the different Spanish autonomous communities on the management of patients with rivaroxaban treatment during the routine clinical practice
By use of Informe de Posicionamiento Terapéutico (Spanish Questionnaire)
Time frame: At recruitment visit
Adherence to rivaroxaban treatment
By use of Morisky-Green questionnaire
Time frame: At recruitment visit
Assess the satisfaction of rivaroxaban treatment
By use of Anti-Clot Treatment Scale (ACTS) questionnaire
Time frame: At recruitment visit
Assess the quality of life in patients
By use of Short-Form 12 Health Survey,version 2 (SF12v2) questionnaire
Time frame: At recruitment visit
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer